Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
- Autores
- Pérez Lloret, Santiago; Meza Rojas, Gloria; Menoni, María Celia; Ruiz, Gabriela; Velásquez, Carolina; Rodriguez, Hernán; Rey, Verónica; Cardinali, Daniel Pedro
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión enviada
- Descripción
- Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia
Fil: Meza Rojas, Gloria. Instituto Mutual de la Salud; Paraguay
Fil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; Paraguay
Fil: Ruiz, Gabriela. Centro Médico Santa Clara; Paraguay
Fil: Velásquez, Carolina. Instituto Mutual de la Salud; Paraguay
Fil: Rodriguez, Hernán. Centro Médico Santa Clara; Paraguay
Fil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; Francia
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación
Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course. - Fuente
- Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)
- Materia
-
PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Pontificia Universidad Católica Argentina
- OAI Identificador
- oai:ucacris:123456789/1624
Ver los metadatos del registro completo
id |
RIUCA_3f787a5dd8788ed0e2e8e1cd01f257c0 |
---|---|
oai_identifier_str |
oai:ucacris:123456789/1624 |
network_acronym_str |
RIUCA |
repository_id_str |
2585 |
network_name_str |
Repositorio Institucional (UCA) |
spelling |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment coursePérez Lloret, SantiagoMeza Rojas, GloriaMenoni, María CeliaRuiz, GabrielaVelásquez, CarolinaRodriguez, HernánRey, VerónicaCardinali, Daniel PedroPREGABALINASUEÑODOLORCALIDAD DE VIDASALUDFil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; FranciaFil: Meza Rojas, Gloria. Instituto Mutual de la Salud; ParaguayFil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; ParaguayFil: Ruiz, Gabriela. Centro Médico Santa Clara; ParaguayFil: Velásquez, Carolina. Instituto Mutual de la Salud; ParaguayFil: Rodriguez, Hernán. Centro Médico Santa Clara; ParaguayFil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; FranciaFil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e InvestigaciónAbstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.Lippincott, Williams & Wilkins2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16240362-56641537-162X (online)10.1097/WNF.0b013e31823df2dcPérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1624instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:20.003Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse |
dc.title.none.fl_str_mv |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
spellingShingle |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course Pérez Lloret, Santiago PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD |
title_short |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_full |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_fullStr |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_full_unstemmed |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
title_sort |
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course |
dc.creator.none.fl_str_mv |
Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro |
author |
Pérez Lloret, Santiago |
author_facet |
Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro |
author_role |
author |
author2 |
Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD |
topic |
PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD |
dc.description.none.fl_txt_mv |
Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia Fil: Meza Rojas, Gloria. Instituto Mutual de la Salud; Paraguay Fil: Menoni, María Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; Paraguay Fil: Ruiz, Gabriela. Centro Médico Santa Clara; Paraguay Fil: Velásquez, Carolina. Instituto Mutual de la Salud; Paraguay Fil: Rodriguez, Hernán. Centro Médico Santa Clara; Paraguay Fil: Rey, Verónica. Paul Sabatier University. Pharmacology Department; Francia Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course. |
description |
Fil: Pérez Lloret, Santiago. Paul Sabatier University. Pharmacology Department; Francia |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/submittedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
submittedVersion |
dc.identifier.none.fl_str_mv |
https://repositorio.uca.edu.ar/handle/123456789/1624 0362-5664 1537-162X (online) 10.1097/WNF.0b013e31823df2dc Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624 |
url |
https://repositorio.uca.edu.ar/handle/123456789/1624 |
identifier_str_mv |
0362-5664 1537-162X (online) 10.1097/WNF.0b013e31823df2dc Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624 |
dc.language.none.fl_str_mv |
eng eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Lippincott, Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott, Williams & Wilkins |
dc.source.none.fl_str_mv |
Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1) reponame:Repositorio Institucional (UCA) instname:Pontificia Universidad Católica Argentina |
reponame_str |
Repositorio Institucional (UCA) |
collection |
Repositorio Institucional (UCA) |
instname_str |
Pontificia Universidad Católica Argentina |
repository.name.fl_str_mv |
Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina |
repository.mail.fl_str_mv |
claudia_fernandez@uca.edu.ar |
_version_ |
1836638330561757184 |
score |
13.070432 |